Navigation Links
New Way to Make Stem Cells?
Date:10/8/2009

Chemicals can do the work previously handled by genes, researchers find

THURSDAY, Oct. 8 (HealthDay News) -- Scientists say they can use chemicals to turn adult cells into patient-specific stem cells instead of relying on potentially cancer-causing genes.

U.S. researchers used chemicals to replace two of the four genes needed to turn adult cells into induced pluripotent stem cells (iPSCs), which are similar to embryonic stem cells.

"Stem cells have the greatest potential to dramatically change and improve the way we treat diseases," study lead author Justin K. Ichida, of the Harvard Stem Cell Institute, said in a news release. "We're very excited about our findings because it means that in the near future we should be able to make limitless supplies of stem cells and possibly replacement cells for patients with diseases."

Previous research identified four genes that can transform adult stem cells into iPS cells. The genes are delivered via a retrovirus that integrates into a cell's DNA. However, the DNA from the virus remains in the cells and, over time, may activate cancer-causing genes.

In this study, the researchers substituted small chemical molecules for two of the genes.

"This discovery is exciting because it demonstrates the feasibility of using chemicals to make safer patient-specific stem cells for transplantation medicine," Ichida said.

"One of the most important things we learned from this study is that with respect to molecular pathways, there may be several ways to convert one type of cell into another. By using a non-biased chemical screening approach, we uncovered a previously unknown way to make stem cells. The big challenge over the next decade will be to figure out how to make the right cells for disease treatment. This approach will be important for achieving that goal."

The study, funded by the New York Stem Cell Foundation, is published online Oct. 8 and in the Nov. 6 print issue of the journal Cell Stem Cell.

More information

The U.S. National Institutes of Health has more about stem cells.



-- Robert Preidt



SOURCE: New York Stem Cell Foundation, news release, Oct. 8, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to San Francisco ... October is the perfect time to visit. , Business Architecture Associates is pleased to offer ... for individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package ...
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a ... lifting weights for strength training and exercise or simply lifting heavy objects, advises Dr. ... position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
(Date:5/23/2017)... IN (PRWEB) , ... May 23, 2017 , ... ... the availability of video chat as a standard feature on its secure clinical ... from text to voice to video depending on the type and urgency of ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: